Head-to-head evidence
HL-400 vs VENT-02
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: NLRP3 · full Parkinson's Disease pipeline
HL-400
Developed by Hangzhou Highlightll Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
VENT-02
Developed by Ventus Therapeutics U.S., Inc.
NCT06822517 · Phase 1/2 · terminated
This is a small but properly randomized, fully blinded, placebo-controlled study; results are not yet posted, and its primary focus is safety rather than a disease outcome, so it supports a moderate rating pending data.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HL-400's landscape · VENT-02's landscape